Compare CING & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CING | HNNA |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1M | 78.0M |
| IPO Year | N/A | N/A |
| Metric | CING | HNNA |
|---|---|---|
| Price | $6.69 | $9.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $37.00 | N/A |
| AVG Volume (30 Days) | ★ 618.4K | 5.6K |
| Earning Date | 03-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.92% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $8.43 |
| 52 Week High | $11.89 | $13.19 |
| Indicator | CING | HNNA |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 46.28 |
| Support Level | $3.77 | $9.42 |
| Resistance Level | $7.92 | $10.33 |
| Average True Range (ATR) | 1.08 | 0.26 |
| MACD | -0.23 | -0.02 |
| Stochastic Oscillator | 10.24 | 40.91 |
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.